

Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Carnwell Lawrence B. Bugaisky Donald J. Featherston

Timothy J. Shea, . Patrick E. Garrett Jeffrey T. Helvey Donald R. Banowit Peter A. Jackman Molly A. McCall Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Albert J. Fasulo 11*

Registered Patent Agents Caren R. Markowicz Andrea J. Kamage Nancy J. Leith Ann E. Summerfield Helene C. Carlson Gaby E. Longsworth Matthew J. Dowd Aaron L. Schwartz Aaron L. Schwartz Angelique G. Uy Boris A. Matvenko Mary B. Tung Katrina Y. Pel Bryan L. Skelton Robert A. Schwartzman John J. Figueroa Timothy A. Doyle Jennifer R. Mahalingappa

- *Admitted only in Maryland †Admitted only in Virginia *Admitted only in Texas •Practice Limited to Federal Agencies

October 29, 2002

RECEIVED

WRITER'S DIRECT NUMBER: (202) 371-2615 INTERNET ADDRESS: FRANKC@SKGF.COM

NOV 0 1 2002

TECH CENTER 1600/2900

Art Unit 1634

Washington, D.C. 20231

Re: U.S. Utility Patent Application

Appl. No. 09/697,079; Filed: October 27, 2000

Methods and Compositions for Cloning Nucleic Acid Molecules For:

Inventors:

Fox et al.

Our Ref:

0942.4460002/RWE/BJD/FRC

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Fee Transmittal Form (PTO/SB/17);
- 2. Amendment and Reply Under 37 C.F.R. § 1.111;
- First Supplemental Information Disclosure Statement; 3. •
- Listing of the cited documents on Form PTO-1449 (1 sheet); 4.
- 5. A copy of each of the two (2) cited documents on Form PTO-1449;
- 6. Our check no. 37166 in the amount of \$180.00 to cover the fee under 37 C.F.R. § 1.17(p); and
- 7. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are

Commissioner for Patents October 29, 2002 Page 2

necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Frank R. Cottingham

Frank R. Cottingle

Attorney for Applicants

Registration No. 50,437

FRC/pcd Enclosures

::ODMA\MHODMA\SKGF_DC1;68676;1



Approved for use through 10/31/2002. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Complete if Known				
O I PE FEE TRANSMITTAL	Application Number	09/697,079			
for FY 2002	Filing Date	October 27, 2000			
	First Named Inventor	Donna K. Fox			
Relatent fees are subject to annual revision.	Examiner Name	Johannsen, D.			
Tratefit lees are subject to armual revision.	Group Art Unit	1634			
TO ELAMOUNT OF AYMENT (\$)180.00	Attorney Docket No.	0942,4460002/RWE/BJD/FRC			

METHOD OF PAYMENT (check one)				FEE CALCULATION (continued)									
The Commissioner is hereby authorized to charge indicated fees and credit any overpayment to:				3. ADDI Large	TIONAL Entity		Entity						
Deposit Account Number	19-0	036			Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee De	escription		Fee paid	
Deposit Account Name	Sterr	e, k	Kessler, Goldstein & Fo	x P.L.L.C.	105	130	205	65	Surcharge - late filing for	ee or oath			
		127	50	227	25	Surcharge - late provisional	filing fee or cover shee	:t					
			139	130	139	130	Non-English specific	cation		EC			
Applicant claims small entity status			147	2,520	147	2,520	For filing a request for	ex parte reexamin	ation	品	1		
See 37 CFR 1.27						920*	112	920*	Requesting publication o	f SIR prior to Examine	er	南	}
2. ⊠ Payment Enclosed:						1,840*	113	1,840*	Requesting publication o	f SIR after Examiner a	action	160	<u></u>
☑ Check ☐ Credit card ☐ Money Order ☑ Other* *Charge any deficiencies or credit any overpayments in the fees or fee calculations of Parts 1, 2 and 3 below to Deposit Account No. 19-0036.				115	110	215	55	Extension for reply wi	thin first month		CENTER 1600/2900	3	
			ALCULATION		116	400	216	200	Extension for reply wi	thin second month		8	
1. BASIC FILING F	EE				117	920	217	460	Extension for reply wi	thin third month]
Large Entity Sma					118	1,440	218	720	Extension for reply wi	thin fourth month	[
Fee Fee Fee Code (\$) Cod	Fo le (\$		Fee Description Fe	ee Paid	128	1,960	228	980	Extension for reply wi	thin fifth month			
101 740 201	37		Utility filing fee		119	320	219	160	Notice of Appeal		į		
106 330 206	16	55	Design filing fee _		120	320	220	160	Filing a brief in suppo	rt of an appeal			1
107 510 207	25	55	Plant filing fee _		121	280	221	140	Request for oral heari	ng	Ì		
108 740 208	. 37	0	Reissue filing fee		138	1,510	138	1,510	Petition to institute a	oublic use proceedi	ing		
114 160 214	8	30	Provisional filing fee _		140	110	240	55	Petition to revive - una	avoidable			
					141	1,280	241	640	Petition to revive - uni	ntentional			•
SUBTOTAL	. (1)	(\$)			142	1,280	242	640	Utility issue fee (or rei	ssue)	ĺ		
					143	460	243	230	Design issue fee		Î		
					144	620	244	310	Plant issue fee				
					122	130	122	130	Petitions to the Comm	nissioner			۱ '
2. EXTRA CLAIM I	FEES	,	Fee from Extra below	Fee Paid	123	130	123	130	Petitions related to pro-	ovisional application	ns		
Total Claime	- 20*	* ==	X =		126	180	126	180	Submission of Infor	mation Disclosure	Stmt	180.00	
			X =		581	40	481	40	Recording each pater property (times number	nt assignment per er of properties)			
Multiple Dependent =		146	740	246	370	Filing a submission at (37 CFR 1.129(a))	ter final rejection						
Large Entity Small	Fe	•	Fee Description		149	740	249	370	For each additional in (37 CFR 1.129(b))	vention to be exam	ined		
Code (\$) Code 103 18 203	9 (\$)		Claims in excess of 20		179	740	279	370	Request for Continue	d Examination (RC	E)		
102 84 202	42		Independent claims in exc	cess of 3	169	900	169	900	Request for expedited	l examination of a	desian		}
104 280 204	140		Multiple dependent claim						application				
108 * 84 209	42		**Reissue independent che patent	aims over original	Other fee	(specify) :							
110 18 210	9		**Reissue claims in exces original patent	s of 20 and over	Other fee	(specify) :							1
SUBTOTAL (2) (\$)					*Reduced by Basic Filing Fee Paid				SUBTOTAL (3) (\$) 180.00				
J. Miller provided by S. Miller and S. Mille												1	٦
SUBMITTED BY					1 4m 11		<u> </u>	Complete (if app			\dashv		
Name (Print/Type) Frank R. Cottingham					Re (Att	gistratior orney/Agent	No.	50,437	Telephone		71-2600	4	
Signature		′,	Page le Cost							Date	OCT.	29,200	21

WARNING: Mormation on this form may become public. Credit card information should not be included in this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. The will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.SKGF Rev. 6/11/02 mnac





Confirmation No.: 7547

Art Unit: 1634

Examiner: Johannsen, D.

Atty. Docket: 0942.4460002/RWE/BJD/FRC

In re application of:

FOX et al.

Appl. No. 09/697,079

Filed: October 27, 2000

For:

Methods and Compositions for

Cloning Nucleic Acid Molecules

Amendment And Reply Under 37 C.F.R. § 1.111

Commissioner for Patents Washington, D.C. 20231

Sir:

In reply to the Office Action dated **July 31, 2002**, (PTO Prosecution File Wrapper Paper No. 14), Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks and arguments. 37 C.F.R. § 1.121 and MPEP 714; and
- (C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R.

§ 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

Please cancel claims 46-48 without prejudice or disclaimer.

Please substitute the following claim 45 for the pending claim 45:

45. (Thrice amended) A composition comprising one or more restriction endonucleases and one or more polymerase inhibitors, wherein said one or more polymerase inhibitors are selected from the group consisting of: an antibiotic, a heavy metal, an acid, a nucleotide analogue, an anionic detergent, a polyanion, captan ((N-[trichloromethyl]-thio)-4-cyclohexene-1,2-dicarboximide), an acidic polysaccharide, a binding protein or peptide, and combinations thereof; wherein said composition does not contain any nucleic acid molecules.

Please add the following claims:

D2

53. (New) A composition comprising one or more restriction endonucleases and one or more polymerase inhibitors, wherein said one or more polymerase inhibitors are one or more antibodies or fragments thereof, and wherein said composition does not contain any nucleic acid molecules.